BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 37385272)

  • 21. The pharmacokinetic diversity of two von Willebrand factor (VWF)/ factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Results from a prospective, randomised crossover study.
    Kessler CM; Friedman K; Schwartz BA; Gill JC; Powell JS;
    Thromb Haemost; 2011 Aug; 106(2):279-88. PubMed ID: 21725579
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-surgical bleeding in patients with ventricular assist devices could be explained by acquired von Willebrand disease.
    Geisen U; Heilmann C; Beyersdorf F; Benk C; Berchtold-Herz M; Schlensak C; Budde U; Zieger B
    Eur J Cardiothorac Surg; 2008 Apr; 33(4):679-84. PubMed ID: 18282712
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antifibrinolytics for heavy menstrual bleeding.
    Bryant-Smith AC; Lethaby A; Farquhar C; Hickey M
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD000249. PubMed ID: 29656433
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High dose of tranexamic acid for treatment of severe menorrhagia in patients with von Willebrand disease.
    Mohri H
    J Thromb Thrombolysis; 2002 Dec; 14(3):255-7. PubMed ID: 12913407
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease.
    Peyvandi F; Castaman G; Gresele P; De Cristofaro R; Schinco P; Bertomoro A; Morfini M; Gamba G; Barillari G; Jiménez-Yuste V; Königs C; Iorio A; Federici AB
    Blood Transfus; 2019 Sep; 17(5):391-398. PubMed ID: 30747707
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Von Willebrand Factor Concentrate Administration for Acquired Von Willebrand Syndrome- Related Bleeding During Adult Extracorporeal Membrane Oxygenation.
    Mazzeffi M; Bathula A; Tabatabai A; Menaker J; Kaczorowski D; Madathil R; Galvagno S; Pasrija C; Rector R; Tanaka K; Herr D
    J Cardiothorac Vasc Anesth; 2021 Mar; 35(3):882-887. PubMed ID: 32758410
    [TBL] [Abstract][Full Text] [Related]  

  • 27. von Willebrand disease and women's health.
    Lee CA; Abdul-Kadir R
    Semin Hematol; 2005 Jan; 42(1):42-8. PubMed ID: 15662615
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions.
    van Galen KP; Engelen ET; Mauser-Bunschoten EP; van Es RJ; Schutgens RE
    Cochrane Database Syst Rev; 2019 Apr; 4(4):CD011385. PubMed ID: 31002742
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Haemostatic management of intraoral bleeding in patients with von Willebrand disease.
    Morimoto Y; Yoshioka A; Sugimoto M; Imai Y; Kirita T
    Oral Dis; 2005 Jul; 11(4):243-8. PubMed ID: 15984956
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance.
    Castaman G; Tosetto A; Federici AB; Rodeghiero F
    Thromb Haemost; 2011 Apr; 105(4):647-54. PubMed ID: 21264446
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prophylactic and therapeutic strategies for intraoperative bleeding in women with von Willebrand disease and heavy menstrual bleeding: A systematic review.
    Eising HP; Punt MC; Leemans JC; Bongers MY
    Blood Rev; 2023 Nov; 62():101131. PubMed ID: 37716881
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease.
    de Wee EM; Sanders YV; Mauser-Bunschoten EP; van der Bom JG; Degenaar-Dujardin ME; Eikenboom J; de Goede-Bolder A; Laros-van Gorkom BA; Meijer K; Hamulyák K; Nijziel MR; Fijnvandraat K; Leebeek FW;
    Thromb Haemost; 2012 Oct; 108(4):683-92. PubMed ID: 22918553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In Vitro Comparison of Recombinant and Plasma-Derived von Willebrand Factor Concentrate for Treatment of Acquired von Willebrand Syndrome in Adult Extracorporeal Membrane Oxygenation Patients.
    Mazzeffi M; Henderson R; Krause E; Rabin J; Madathil R; Chow J; Grazioli A; Meyer M; Wu Z; Tanaka K
    Anesth Analg; 2022 Feb; 134(2):312-321. PubMed ID: 34903705
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnosis and management of adult patients with von Willebrand disease in South Australia.
    Rodgers SE; Lloyd JV; Mangos HM; Duncan EM; McRae SJ
    Semin Thromb Hemost; 2011 Jul; 37(5):535-41. PubMed ID: 22102197
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An evaluation of von Willebrand factor (recombinant) therapy for adult patients living with severe type 3 von Willebrand disease.
    Hancock JM; Escobar MA
    Expert Rev Hematol; 2023 Mar; 16(3):157-161. PubMed ID: 36861346
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of a von Willebrand factor/factor VIII concentrate (Wilate®): a single centre experience.
    Batty P; Chen YH; Bowles L; Hart DP; Platton S; Pasi KJ
    Haemophilia; 2014 Nov; 20(6):846-53. PubMed ID: 25102895
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease.
    Lubetsky A; Schulman S; Varon D; Martinowitz U; Kenet G; Gitel S; Inbal A
    Thromb Haemost; 1999 Feb; 81(2):229-33. PubMed ID: 10063997
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cyclical progestogens for heavy menstrual bleeding.
    Bofill Rodriguez M; Lethaby A; Low C; Cameron IT
    Cochrane Database Syst Rev; 2019 Aug; 8(8):CD001016. PubMed ID: 31425626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evolution of replacement therapy for von Willebrand disease: From plasma fraction to recombinant von Willebrand factor.
    Peyvandi F; Kouides P; Turecek PL; Dow E; Berntorp E
    Blood Rev; 2019 Nov; 38():100572. PubMed ID: 31229334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.